Literature DB >> 559720

Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.

D T Fearon, K F Austen.   

Abstract

Cleavage of C3 by the alternative complement pathway occurs in at least two distinct phases: continuous low grade generation of C3b by the interaction of native C3, B, D, and P, and subsequent amplified cleavage of C3 by the interaction of C3b, B, D, and P which forms the amplification convertase, P,C3b,Bb. Transition to C3b-dependent amplification is necessary to achieve substantial C3 cleavage and is normally limited by the combined action of C3b inactivator (C3bINA) and betalH. An activator of the alternative pathway, such as rabbit erythrocytes (E(r)), provides sites that protect bound C3b and P,C3b,Bb from the action of these regulatory proteins and permits C3b deposited by the low grade fluid phase reaction to assemble a membrane-associated amplification convertase which can deposit additional protected C3b. Under conditions in which the control proteins, C3bINA and beta1H, almost completely inactivated C3b bound to sheep erythrocytes (E(s)), which does not activate the alternative pathway, the function of C3b bound to E(r) was diminished by less than one-fifth. Further, the P- stabilized amplification convertase on E(r) was 10-fold less sensitive to beta1H-mediated decay-dissociation than the convertase on E(s). The addition of E(r) to a regulated mixture of purified C3, B, D, P, C3bINA, and beta1H resulted in amplified inactivation of C3 and B by formation of the amplification convertase on E(r) as indicated by its lysis with subsequent exposure to C3-C9. In contrast, E(s) did not advance the low grade fluid phase inactivation of C3 and B to amplified inactivation and the cell was not converted to an intermediate susceptible to lysis by C3- C9. Since E(r) and E(s) did not differ in their inefficient fixation of C3b generated during an unregulated fluid phase reaction, the activating capacity of E(r) must reside in its protection of bound C3b and P, C3b,Bb from the regulatory proteins rather than in enhanced capacity to bind C3b from the fluid phase. When the reaction is limited to low grade fluid phase turnover, introduction of E(r) but not E(s) results in a 100-fold increase in the deposition of C3b, indicating that surface-dependent activation of the alternative pathway is characterized by efficient deposition of C3b on the initiating surface. Thus, the activating surfaces advance the interaction of the alternative pathway proteins to the amplification phase because of the selective inability of the regulatory proteins to deal with their substrates when deposited on these surfaces and results in a specificity that is not necessarily dependent on adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 559720      PMCID: PMC2180739          DOI: 10.1084/jem.146.1.22

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  39 in total

1.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

2.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

3.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

4.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

5.  Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

6.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

7.  An alternative mechanism for the properdin system.

Authors:  R A NELSON
Journal:  J Exp Med       Date:  1958-10-01       Impact factor: 14.307

8.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

9.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.

Authors:  R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  59 in total

1.  In vitro complement activation by rabbit lymphocytes and thymocytes in autologous serum.

Authors:  A B Wilson; P J Lachmann; R R Coombs
Journal:  Immunology       Date:  1979-05       Impact factor: 7.397

2.  Limited tryptic cleavage of complement factor H abrogates recognition of sialic acid-containing surfaces by the alternative pathway of complement.

Authors:  V Koistinen
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

3.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

4.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

Authors:  R D Schreiber; M K Pangburn; P H Lesavre; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

5.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

6.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

7.  Complement activation in asymptomatic patients with sickle cell anaemia.

Authors:  W A Wilson; E J Thomas; J G Sissons
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

Review 8.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

9.  Isolation and characterization of a low molecular weight complement inhibitor present in normal human serum.

Authors:  P J Baker; S G Osofsky
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

10.  Restoration by normal human immunoglobulin G of deficient serum opsonization for Streptococcus pneumoniae in sickle cell disease.

Authors:  A B Bjornson; J S Lobel; P I Magnafichi; B C Lampkin
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.